EUVIMEDEUVIMED entdecken
Crossref

Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors

Jietao Ma, Jun Song, Xiaofang Yi, Shuling Zhang, Letian Huang, Li Sun, Ruolin Gao, Chengbo Han

International Immunopharmacology · 2024-05 · 132 · 112006

DOI: 10.1016/j.intimp.2024.112006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-05. Verfasst von Jietao Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Dynamins, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate the influence of dynamin-related protein 1 (Drp1)-regulated T cells on the antitumor effects of poly (ADP-ribose) polymerase inhibitors (PARPi) combined with programmed cell death protein 1 (PD-1) inhibitors to identify potential targets for enhancing immunotherapy efficacy. We found that T cells with high expression of Drp1 promoted the inhibitory and killing effects of the PARPi and PD-1 inhibitor combination on lung cancer cells in vivo and in vitro. This synergistic mechanism involves Drp1-regulated promotion of activation, migration, and intratumor infiltration of effector T cells; inhibition of negative immunomodulatory cells in the tumor microenvironment; and suppression of PARPi-induced upregulation of PD-L1 expression in tumor cells. These findings suggest that Drp1 could serve as a new target for comprehensively improving the tumor microenvironment, enhancing immunotherapy efficacy, and reversing immunotherapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentDynaminsImmune Checkpoint InhibitorsLung NeoplasmsT-LymphocytesProgrammed Cell Death 1 ReceptorPoly(ADP-ribose) Polymerase InhibitorsAnimalsHumansMiceCell Line, TumorB7-H1 AntigenFemaleImmunotherapy

Stichwörter der Autor:innen

Dynamin-related protein 1Lung cancerPARP inhibitorPD-1 inhibitorTumor microenvironment

Substanzen

DynaminsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPoly(ADP-ribose) Polymerase InhibitorsB7-H1 AntigenDnm1l protein, mouse

Autor:innen und Institutionen

  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei,…
  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Electronic address: hanchengbo@sj-hospital.org.

Zitieren

APA

Ma, J., Song, J., Yi, X., Zhang, S., Huang, L., Sun, L., Gao, R., & Han, C. (2024). Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors. International Immunopharmacology, 132, 112006. https://doi.org/10.1016/j.intimp.2024.112006

Vancouver

Ma J, Song J, Yi X, Zhang S, Huang L, Sun L, et al. Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors. International Immunopharmacology. 2024;132:112006. doi:10.1016/j.intimp.2024.112006

BibTeX
@article{Ma2024,
  author = {Ma, Jietao and Song, Jun and Yi, Xiaofang and Zhang, Shuling and Huang, Letian and Sun, Li and Gao, Ruolin and Han, Chengbo},
  title = {Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {132},
  pages = {112006},
  doi = {10.1016/j.intimp.2024.112006}
}
Kostenlos starten →